Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
10.72B
Market cap10.72B
Price-Earnings ratio
14.83
Price-Earnings ratio14.83
Dividend yield
Dividend yield
Average volume
3.62M
Average volume3.62M
High today
$41.75
High today$41.75
Low today
$40.55
Low today$40.55
Open price
$41.63
Open price$41.63
Volume
2.24M
Volume2.24M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$32.38
52 Week low$32.38

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $41.24. The company's market cap stands at 10.72B, with a P/E ratio of 14.83.

As of 2026-03-14, Exelixis(EXEL) stock has fluctuated between $40.55 and $41.75. The current price stands at $41.24, placing the stock +1.7% above today's low and -1.2% off the high.

Exelixis(EXEL) shares are trading with a volume of 2.24M, against a daily average of 3.62M.

During the past year, Exelixis(EXEL) stock moved between $32.38 at its lowest and $49.62 at its peak.

During the past year, Exelixis(EXEL) stock moved between $32.38 at its lowest and $49.62 at its peak.

EXEL News

Simply Wall St 22h
Assessing Exelixis Valuation After Analysts Lift 2026 Earnings Forecasts

Exelixis (EXEL) is back on investor radars after six analysts raised their earnings forecasts for fiscal 2026, citing the company’s oncology pipeline and their...

Assessing Exelixis Valuation After Analysts Lift 2026 Earnings Forecasts

Analyst ratings

50%

of 22 ratings
Buy
45.5%
Hold
50%
Sell
4.5%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.